INmuneBIO: Funding, Investors & Team (Oct 2026)
INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
INmuneBIO has raised $62.7M across 3 funding rounds on record, the most recent an undisclosed round of $13.0M announced in Sep 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
INmuneBIO Company Profile and Key Stats
Latest funding round on record: Sep 2024.
INmuneBIO Funding Rounds
INmuneBIO raised $40.0M in a Post-IPO Equity announced in Jul 2021.
2.8 years later, an undisclosed round of $9.7M was announced in Apr 2024.
5 months later, an undisclosed round of $13.0M was announced in Sep 2024.
INmuneBIO Founders and Leadership Team
Contact details for the INmuneBIO team: 3 of 4 have an email address on file.
Start 14-day free trial →INmuneBIO Funding Compared to Other Biotechnology Startups
INmuneBIO's latest round of $13.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like INmuneBIO in Biotechnology and La Jolla
Companies Similar to INmuneBIO
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
INmuneBIO Funding FAQs
What does INmuneBIO do?
INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
How much funding has INmuneBIO raised?
INmuneBIO has raised $62.7M across 3 rounds on record. The most recent is an undisclosed round of $13.0M announced in Sep 2024.
When did INmuneBIO last raise funding?
INmuneBIO's most recent funding round on record is an undisclosed round of $13.0M, announced in Sep 2024.
Who founded INmuneBIO?
FundedIQ lists Mark Lowdell (Founder), Raymond J Tesi (Founder) at INmuneBIO.
Who is the CEO of INmuneBIO?
Kelly Ganjei is listed as CEO at INmuneBIO.
Where is INmuneBIO headquartered?
INmuneBIO is based in La Jolla, California, United States.
How many employees does INmuneBIO have?
INmuneBIO is in the 11-50 employee band.
How does INmuneBIO's funding compare to other Biotechnology startups?
INmuneBIO's latest round of $13.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's INmuneBIO Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for INmuneBIO is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.